Role of DLC1 tumor suppressor gene and MYC oncogene in pathogenesis of human hepatocellular carcinoma: potential prospects for combined targeted therapeutics (review).

摘要: Hepatocellular carcinoma (HCC) is the third leading cause of cancer death, and its incidence increasing worldwide in an alarming manner. The development curative therapy for advanced metastatic HCC a high clinical priority. genome complex heterogeneous; therefore, identification recurrent genomic related gene alterations critical developing applications diagnosis, prognosis targeted disease. This article focuses on recent research progress our contribution identifying deciphering role defined genetic pathogenesis HCC. A significant number genes that promote or suppress cell growth have been identified at sites reorganization. Notwithstanding accumulation multiple alterations, highly changes single chromosome can alter expression oncogenes tumor suppressor (TSGs) whose deregulation may be sufficient to drive progression normal hepatocytes malignancy. distinct pattern imbalances includes loss DNA copy (associated with heterozygosity) TSG-containing 8p gain regional amplification protooncogenes 8q. Even though relatively small, it carries unusually large TSGs, while, other side, several are dispersed along Compelling evidence demonstrates DLC1, potent TSG 8p, MYC oncogene 8q play human Direct their genesis has obtained mosaic mouse model. Knockdown DLC1 helps induction hepatoblast transformation vitro, vivo. Therapeutic interventions, which would simultaneously target signaling pathways governing both functions hepatocarcinogenesis, could result treatment liver cancer.